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TreatmentGadolinium based contrast agents (GBCAs) play an important role in the diagnostic evaluation of many
patients. The safety of these agents has been once again questioned after gadolinium deposits were
observed and measured in brain and bone of patients with normal renal function. This retention of
gadolinium in the human body has been termed “gadolinium storage condition”. The long-term and
cumulative effects of retained gadolinium in the brain and elsewhere are not as yet understood. Recently,
patients who report that they suffer from chronic symptoms secondary to gadolinium exposure and
retention created gadolinium-toxicity on-line support groups. Their self-reported symptoms have recently
been published. Bone and joint complaints, and skin changes were two of the most common complaints.
This condition has been termed “gadolinium deposition disease”. In this reviewwewill address gadolinium
toxicity disorders, from acute adverse reactions to GBCAs to gadolinium deposition disease, with special
emphasis on the latter, as it is the most recently described and least known.Hospital Garcia de Orta,
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Gadolinium-enhanced MRI impacts diagnosis and treatment
strategies by detecting a wide variety of pathologic processes that
would otherwise be undetectable with unenhanced MRI or other
imaging modalities. Gadolinium based contrast agents (GBCAs) have
been in clinical use for almost 30 years, with more than 300 million
doses administeredworldwide [1,2]. The general safety proﬁle of these
agents has been exceptional; apart from acute adverse events, the
great majority of which are mild, and nephrogenic systemic ﬁbrosis
(NSF), a rare life-threatening condition seen in patients with severe
renal failure, few gadolinium-related toxicities have been reported. A
number of conditions may inﬂuence gadolinium toxicity, and renal
function andmolecular structure of theGBCAare themostwell known.
GBCAs can be classiﬁed according to their biochemical structure
as linear or macrocyclic and further subdivided according to their
charge as ionic or non-ionic. Macrocyclic chelates are more stable
than linear chelates, and ionic linear is more stable than the nonionic
linear ones [3]. Stability is the ability of the ligand to retain the Gd3+
ion within the complex. Since free gadolinium (Gd3+) is toxic,
stability is a critical factor in gadolinium toxicity.Most GBCAs in clinical use are nonspeciﬁc extracellular
contrast agents, which, similarly to iodine-based contrast agents,
are cleared almost exclusively by the kidneys. Patients with renal
impairment have reduced GBCA elimination, and the gadolinium
complex remains inside the body for extended periods, allowing
dissociation to occur [3,4]. Renal function has been considered a
critical determinant of subacute gadolinium toxicity, which became
recognized by the radiology community when the association
between NSF and GBCA exposure was documented.
In a similar time frame to the recognition of the relationship
between gadolinium and NSF, reports were published describing the
presence of gadolinium in bone in patients with normal kidney
function undergoing hip replacement [5,6]. The potential implication
of this was not fully appreciated, until almost a decade later when
gadolinium was found in brain tissue [7–9].
In this review we will describe the spectrum of reported
gadolinium adverse effects and toxicity.2. Acute adverse events
When used at clinically approved doses (0.1 to 0.2 mmol/kg for
most agents) GBCAs have a long-standing and excellent cumulative
safety proﬁle and are extremely well tolerated by the vast majority of
patients. The overall adverse event rate ranges between0.07% and2.4%
[10–12]. Acute adverse events (AE) can be divided according to its
mechanism into immediate hypersensitivity (allergic-like) reactionsnicalKey.com by Elsevier on June 30, 2017.
. Elsevier Inc. All rights reserved.
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imply an immune response to the whole or part of the GBCA) or
physiologic reactions (coldness, warmth, or pain at the injection site,
nausea with or without vomiting, headache, paresthesias, and
dizziness). According to severity, AE can be classiﬁed into mild
(self-limited with signs and symptoms showing no evidence of
progression), moderate (more pronounced symptoms, such as
bronchospasm, laryngeal edema, and/or generalized erythema) or
severe (life threatening, including severe laryngeal edema, convul-
sions, profound hypotension, unresponsiveness, arrhythmia, and/or
cardiopulmonary arrest) [13].
Most reactions are mild and physiologic in nature. Allergic-like
reactions are uncommon and vary in frequency from 0.004% to 0.7%
[13]; lower than the rate of incidence for acute adverse reactions
associated with low-osmolar nonionic iodinated contrast media
used for CT scans, which itself is already low (0.2%) [14].
Severe life-threatening anaphylactic and fatal reactions do occur,
but are exceedingly rare (0.001% to 0.01%) [13,15–17], with only 40
deaths reported in 51 million GBCA doses administered between
2004 and 2009 [18]. The rarity of severe reactions makes it difﬁcult
to analyze accurately any differences between the reactions
associated with individual GBCAs.
Patients with asthma and various other allergies may have a mild
increased risk for an allergic-like reaction to GBCAs compared to the
general population, but many institutions do not have special
procedures for these patients given the extremely low overall reaction
rate for these agents [10]. Jung et al. [14] also identiﬁed female gender
and the number of exposures to MR contrast media as risk factors.
Previous allergic reaction to a GBCA [14,18] is also a risk factor. The
recurrence rate of hypersensitivity-like reactions is nearly 30% [14].
Indeed, if a patient has a history of reaction to a particular GBCA and
further MRI exams are needed, it is recommended to change to a
different GBCA, and appropriate premedication with antihistamine
and systemic corticosteroid should be considered according to the
severity of the previous hypersensitivity reactions [14].
At present there is no evidence to suggest that there is any
difference in the incidence of acute adverse events between individual
contrast agents. Themost appropriate sources for information on acute
adverse events are published phase 3 trial results, and phase 4 studies
that do not have a commercial association.
3. Nephrogenic systemic ﬁbrosis (NSF)
NSF was linked with GBCAs' exposure in patients with renal
insufﬁciency in 2006 [19,20]. It is a debilitating and potentially
life-threatening disease characterized by widespread progressive
tissue ﬁbrosis. Currently, it is widely accepted that the two essential
underlying factors for NSF are renal failure and GBCA administration,
but the exact underlying mechanism is not fully elucidated. NSF has
been almost completely eliminated since the mid-2009 by screening
patients for the presence of renal disease, by performing unenhanced
studies or half-dose GBCA studies in patients at high risk, and
changing the agents used avoiding high-risk GBCAs in patients with
substantial renal disease. The changes in practice patterns that have
led to successful prevention of NSF have been crucial in reassuring
the public and health care professionals, and had resulted in a
decrease in anxiety associated with use of these contrast agents,
until 2014, when gadolinium deposition in brain tissue was noticed.
4. Gadolinium toxicity: reported cases of miscellaneous toxicity
4.1. Non-neurological
Individual case reports have described a variety of toxic
occurrences from GBCAs [21]. An acute nephrotoxic effect wasDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa 
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function who had 2 consecutive vascular imaging procedures
employing GBCA administration and a few days later after the
second study the patient developed acute renal failure. A renal
biopsy revealed acute tubular necrosis Akgun et al. [22]. Another
report described recurrent acute pancreatitis in a 58-year-old
woman following gadobenate dimeglumine (MultiHance®) admin-
istration [23]. Pancreatitis ensued approximately 3 h after initial
GBCA exposure and recurred upon subsequent administrations. In
another case report, a previously asymptomatic 45-year old woman
experienced upper abdominal pain and vomiting 4 h after cranial
MRI with gadodiamide (Omniscan®), twelve hours after the onset of
her abdominal symptoms, an MRI was performed that revealed
severe necrotizing pancreatitis requiring surgical intervention [24].
Gathings et al. [25] recently described histologic features similar
to NSF in two patients with normal renal function after receiving
gadodiamide (Omniscan®). The authors named it as
gadolinium-associated plaques. These plaques (sclerotic bodies)
had initially been thought to be pathognomonic for NSF, but in the
report by Gathings et al. both patients had no NSF and only one had
renal disease [25]. The patient who did not have renal disease
received high doses of gadolinium, suggesting that similar histologic
features may be present in patients without NSF. This may represent
part of the spectrum of GDD.
4.2. Neurological
Gadolinium neurotoxicity was described in two case reports of
presumed gadolinium induced encephalopathy, by Maramattom et
al. [26] and Hui et al. [27]. In the ﬁrst case a 57-year-old womanwith
end stage renal failure developed encephalopathy after repeated
intravenous gadolinium-enhanced MR imaging, while the serum
free gadolinium level was 28,591 ng/mL (50,000 nmol/mL). Im-
provement in mental status coincided with the clearance of serum
gadolinium and resolution of CSF hyperintensity. In the second case
the patient's mass spectrometry detected 23,000 nmol/mL of
gadolinium in a CSF sample.
Miller et al. [28] recently described the MRI changes occurring in
the brain of a male patient who received 35 GBCA doses of a linear
agent (gadopentetate dimeglumine) when he was between the ages
of 8 and 20 years. This individual was diagnosed at age 5 years with
a rhabdomyosarcoma of the left orbit, underwent surgery, chemo-
therapy, and external beam radiation and subsequent MR surveil-
lance. At 7 years of age he underwent the ﬁrst of 35
contrast-enhanced MRI brain examinations. His medical history is
notable for several intercurrences. However at 21 years old, he had
no intracranial lesion on MRI, signiﬁcant visible treatment-related
intracranial structural abnormality, or signiﬁcant documented
medical problem. No skin lesions were apparent, and renal and
hepatobiliary function testing was always normal. Recent neuropsy-
chological testing, suggested difﬁculties with executive functioning
(e.g., planning, working memory, organization, and cognitive
ﬂexibility), visual memory and reasoning, reading comprehension,
and math abilities. Despite the gadolinium accumulation in the basal
ganglia, deﬁnite conclusions could not be drawn regarding the
cognitive delay and gadolinium due to the considerable brain
external beam radiation and proton beam therapy.
5. Gadolinium storage condition
The storage state of gadolinium in the body [29] has received
considerable international interest and multiple publications.
Gadolinium presence was originally observed in bone [5,6,30] and
more recently in the brain [7–9,31–39] in patients with normal
renal function.Central from ClinicalKey.com by Elsevier on June 30, 2017.
opyright ©2017. Elsevier Inc. All rights reserved.
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evaluation of tissue from patients who had had normal kidney
function when gadolinium was administered to them. The authors
found proportionate content of brain and bone, with bone having
approximately 20 times the concentration of gadolinium compared
to brain, with both linear and macrocyclic agents [9]. What is
currently known, is that gadolinium is retained in body tissues,
regardless of renal function or even GBCA stability [5–9]. Higher
concentrations appear to occur in patients with renal impairment
[40] or after exposure to the less stable GBCAs [41,42]. This entity of
simple retention in tissues has been recently termed “gadolinium
storage condition (GSC)” [29]. Early reports of gadolinium accumu-
lation in the brain and bone of patients with normal renal function
who have undergone multiple gadolinium contrast administrations
were initially described in adults. Recent studies in children emulate
the reported ﬁndings in adults, reﬂecting gadolinium deposition in
the brain [28,43,44]. Whether the accumulated gadolinium is
dechelated and associated with different molecules, or chelated in
its original formulation is not completely clear.
In a recently published meta-analysis, Lancelot [45] reviewed the
data on radiolabelled studies showing the presence of a deep
compartment for gadolinium storage in the body. He showed that
the toxicokinetic proﬁle of different GBCAs varied according to their
chemical structure. In this regard, he showed that gadoterate
meglumine (Dotarem®), a macrocyclic GBCA, had a much faster
blood clearance than linear GBCAs, which appears to be related to
different thermodynamic stability of these agents. Radiolabelled
investigation showed that the ligand of gadodiamide (Omniscan®)
underwent γ (residual excretion phase) elimination at the same fast
rate as the entire chelate of Dotarem®, while the gadolinium atom
showed much more prolonged γ rate, suggesting that the chelate
had disassociated and the gadolinium was retained in the body.
Gadolinium chelate dissociation occurs in vivo, a mechanism that
may explain their long-lasting retention and slow release from bone.
This seems to show that dechelated gadolinium, especially in the
setting of linear agent use, tend to persist in tissue stores and bound
to host chemicals, while the ligand is eliminated in the urine.
6. Gadolinium deposition disease
6.1. Deﬁnition
Gadolinium deposition disease (GDD) represents symptoms in
patients with normal renal function who have received a GBCA
agent. The main difference between GSC and GDD is that in GSC
gadolinium is presumably inert in the tissues, while in GDD the
presence of gadolinium generates considerable symptomatology. In
order for GDD to occur, our opinion is that the host generates an
immunologic response that is host-destructive, and furthermore we
believe that it is dependent on the genetic susceptibility of each
individual. There are thus two components that we consider to be
essential in GDD: 1) the presence of gadolinium in the body, and 2)
the host response to its presence. The recognition of both of these
components will become essential, as appropriate therapy will most
likely involve addressing both.
A recent survey publication [46] described the most common
symptoms of presumed GDD. In a follow-up survey, these authors
addressed more speciﬁcally symptoms described by patients. Not
surprisingly many of these symptoms were analogous to NSF, but
less severe. The principal symptoms included: bone pain (peripheral
but also central), skin and subcutaneous tissue burning pain
(peripheral arm and leg [glove and sock] but also central), and in
late stage disease (N3 months) progressive thickening and discolor-
ation of the skin and subcutaneous tissue of the distal arms and legs
occurs. Apparently distinct from NSF is the feature of disorientedDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisb
For personal use only. No other uses without permissiomentation (patients often term “brain fog”) that is frequently
described by sufferers, which can be disabling to the point that the
person may be unable to continue their normal employment. At the
present time it is unclear whether “brain fog” may also be seen in
NSF, but is has been described with toxicity of other heavy metals,
such as lead.
6.2. Pathophysiology
The onset of GDD seems to arise earlier than with NSF, typically
within hours to days of GBCA administration, rather than weeks to
months. Our present hypothesis to explain the earlier onset of this
condition, is that this disease may be a blend of an acute adverse
event, that is a polypeptide-mediated response, with a subacute
adverse event, that is cell-mediated.
The acute response component may reﬂect release of cytokines
and chemokines, as has been described in a study by Wermuth et al.
[47], in which the authors found that all GBCAs induced speciﬁc
cytokine and chemokine elaboration. This likely explains why
apparently a greater range of GBCAs (including macrocyclic agents)
cause GDD, unlike both NSF or GSC which are more strongly related
to weaker chelates. In this fashion GDD shares similarities with
GBCA-induced acute adverse reactions, and the contribution of acute
immune effects may explain why this condition may also be
observed even with more stable agents. As with allergic reactions
of other types, the reaction can occur both after the ﬁrst event, but
also at a later time following multiple previous administrations,
which had not previously caused a reaction. GDD has been described
after a single administration of GBCA, but also following multiple
prior GBCA administrations, where no reaction had occurred with
the early administrations.
The subacute immunologic response is probably analogous to
NSF mechanism that has been described as mediated by CD 34+
ﬁbrocytes, which congregate in the subcutaneous tissues in the
peripheral arms and legs. We expect that a similar cell-based
immunologic response must also be occurring in the late
stage of GDD, although not yet histologically proven. It is likely
that these CD 34+ ﬁbrocytes are part of the myeloid cell family of
immune-responder cells.
Disease processes based on accumulation of material are not rare.
One disease that may bear a lot of similarity to GSC vs. GDD and
gadolinium presence, is liver disease related to fat accumulation:
non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato-
hepatitis (NASH). As with GSC and GDD the difference between the
two is based on the interplay of host genetics and immunology, to
the presence of fat in the liver. NASH is associated with deﬁned
genes, which is not associated with NAFLD [48,49].
Our opinion is that in GDD there may be a genetic abnormality in
metabolizing heavy metals. Genetic variability may explain the low
incidence of GDD in comparison with the number of patients
exposed to GBCAs, and also the variable severity of the symptoms.
In an analogous fashion, a recent paper described inter-individual
variability and genetic inﬂuences on cytokine responses, but in this
report to bacteria and fungi [50]. They reported that there is
considerable variability between individuals on the extent of
cytokine release to such pathogens, from negligible to complete
host-destruction, which is similar to the variability of the severity of
disease reported by patients with GDD. The authors of this research
also found that the variable immune response is apparently
gene-mediated.
6.3. Epidemiology
Discussion had by an author in this review with many of the
sufferers in the MRI-gadolinium-toxicity support group andoa Central from ClinicalKey.com by Elsevier on June 30, 2017.
n. Copyright ©2017. Elsevier Inc. All rights reserved.
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tion, suggests that the great majority of these individuals are
European-origin white, and many are female. This may represent a
selection bias, as these are volunteers from on-line advocacy groups.
Thesepatients appearwell educated, have access to informationon the
Internet, and have motivation and intellectual curiosity sufﬁcient to
look for a reason for their symptoms; and this stereotype may
inﬂuence our current thinking on epidemiology. However, our opinion
is that it may represent a genetic susceptibility. As it appears to be a
condition of difﬁculty with metal metabolism, the condition is
reminiscent of another disease of metal handling, genetic hemochro-
matosis, which is a gene-based disease that occurs inwhite individuals
of Celtic origin. It may be that difﬁculty with processing and/or
metabolizing metals, or over-reaction to them, may be primarily a
European-origin Caucasian person's disease. As further indirect proof
of GDD being a predominantly white person's genetic disease, the
initial and subsequent publication of gadolinium retained in the
dentate nucleus and globus palliduswasmade byKanda et al. [31] on a
Japanese population, hence simple storage is likely a universal
phenomenon of gadolinium exposure, and especially of linear agents
[33,34,36–39]. Yet there are nomajor series of NSF coming from Japan,
South Korea or China [51,52]. Underdiagnosis of NSF is unlikely to
explain the numerical discrepancy of NSF incidence in Asian countries
compared [52]. Furthermore, although the authors are aware of many
cases in North America, and individuals in Australia and Europe
complainingof symptomsofGDD,weareunawareof any reports at the
present time from Asian countries.
The incidence of GDD and GSC are at present difﬁcult to predict.
Regarding GSC it is likely that all individuals who have received 5 or
greater MRI studies with a GBCA will have tissue retention of
gadolinium, however it seems that the amount of deposited
gadolinium depends on the stability of the applied GBCA, being
less with macrocyclic agents. Our best guess is that this may number
in the millions of individuals. In the great majority of these
individuals the gadolinium appears to be inert. Communication
with patient activist groups suggest that probably the number of
declared sufferers of GDD are somewhere in the 200 range, whichwe
interpret that the real number is in the thousands. This may be a
similar incidence to severe acute allergic reactions.
6.4. Diagnosis
Diagnoses include clinical symptoms after exposure to standard
dose, or greater, of any GBCA and conﬁrmation of gadolinium
retention [53]. Our current impression is that the most reliable
laboratory test to conﬁrm gadolinium deposition may be 24-h urine
test, which should be performed at least 30 days after GBCA
administration. The explanation for this is that we believe that
24-h urine gadolinium likely gives the best window for ‘mobile’
circulating gadolinium in the host, as it reﬂects a 24-h window. In
contrast, a blood sample for gadolinium gives just a snap shot view of
the circulating gadolinium at the time the test is taken, providing a
vastly lesser amount of gadolinium and ignoring the likelihood of
diurnal variation in gadolinium release. Testing tissues should
accurately detect gadolinium, but this is more invasive, generally
painful, and much more expensive. As importantly, tissues such as
bone, which is the largest repository, are nonspeciﬁc, and virtually
everyone who has received perhaps even a single dose of GBCA,
especially if it is a linear nonionic agent, will have bone deposition
(GSC), but only a small fraction of these will have GDD.
6.5. Treatment
The consideration of treatment for sufferers is early. Based on the
hypothesis that GDD may be a genetic abnormality in metabolizingDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa 
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combination of re-chelation and immune system modulation [46].
For some years patients who have become symptomatic after
GBCA, and who have felt that this arose due to the recent
administration of a GBCA, have been dismissed by mainstream
physicians. Our explanation is that their physicians considered that
since the patients had normal renal function they could not have
gadolinium toxicity, since the recognized disease, NSF, only occurred
in patients with advanced renal failure. Rejected by mainstream
medicine, they have had to seek out more fringe-of-medicine based
therapy. Many of these patients have experienced some success with
rechelation therapy, but the problem has been the lack of
scientiﬁcally-guided optimization of this treatment. Chelation
centers generally use ethylenediaminetetraacetic acid (EDTA) as
the chelation agent, but EDTA, although showing good thermody-
namic stability for smaller atomic number elements, such as calcium,
is actually a rather poor chelator for heavier cations such as
gadolinium. Probably the best available chelator is pentetic acid
diethylenetriaminepentaacetic acid (DTPA), which has good ther-
modynamic stability and approximately 300,000 times more afﬁnity
than EDTA for gadolinium. The worry with EDTA therefore is that it
may dislodge gadolinium from tissue stores, but may simply
translocate it somewhere else in the body. In contrast, DTPA has
the binding strength to not only pick up gadolinium but also retain it
long enough to be removed from the body through renal excretion,
which is the usual route for GBCA elimination. Other chelators have
also been evaluated. Leung et al. [54] reported that deferoxamine
doubled the urinary excretion of Gd, but had no effect on serum Gd
levels in an NSF patient and concluded that it was too weak of a
chelator for Gd removal. While not reported for Gd+3, the log
thermodynamic stability constant of deferoxamine for a related
lanthanide, La+3, is 10.9, which is many orders of magnitude lower
than the log-binding constant of DTPA for Gd+3, which is 22.5.
Tackling of the issue of tempering the host response to gadolinium is
a more complex subject that is far from developed. Likely the optimal
agent is one that has a proﬁle for dampening release of cytokines/
chemokines that best matches the proﬁle of the cytokines/chemokines
released in the presence of gadolinium.We strongly discourage random
experimentation with agents. Also it appears that the vast array of
various other treatments patients have tried or been subjected to, either
have no effect (at best) but also cause additional harm, in addition to the
underlying harm from GDD. The only ancillary treatment that may offer
somebeneﬁt are simple anti-inﬂammatories (ibuprofen,ASA, naproxen)
and antihistamines (diphenhydramine). Beneﬁt though seems to be
minimal with these. Eventually targeted immune modulators are ideal
agents, which likely also will be agents with particular value to treat
severe acute allergic reactions.
7. Summary
Gadolinium toxicity is a family of disorders including acute
adverse reactions, NSF, GSC, and GDD. To the present time, little is
known about GDD and most assumptions are hypotheses borrowed
from empirical information on other disease processes. As summary,
what is known is that GDD is a real entity, likely very uncommon,
related to GBCA exposure, similar to NSF but seen in patients
with normal renal function (also seen in those with poor function),
and caused by a range of GBCA agents irrespective of their
molecular structure. Our hypotheses is that the pathophysiologic
mechanism is a combination or summation of acute and subacute
allergic reactions (polypeptide [cytokine] and cell-based [ﬁbrocytes,
mononuclear phagocytes], respectively), gene-based, affecting
European-origin Caucasians with female predominance, amenable
to treatment with rechelation (almost certainly) and possibly with
targeted-host-immune-modulator agents.Central from ClinicalKey.com by Elsevier on June 30, 2017.
opyright ©2017. Elsevier Inc. All rights reserved.
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